Nucala

DRUG2 trials

Sponsors

Mayo Clinic, GlaxoSmithKline

Conditions

Chronic Spontaneous UrticariaChurg-Strauss SyndromeEosinophilic Granulomatosis With Polyangiitis

Early Phase 1

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

CompletedNCT03494881

Mayo ClinicChronic Spontaneous Urticaria

Start: 2019-07-30End: 2025-02-25Updated: 2025-08-27

Unknown Phase

NUCALA® Special Drug Use Investigation (EGPA, Long-term)

CompletedNCT03557060

GlaxoSmithKlineChurg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis

Start: 2018-06-25End: 2025-07-30Updated: 2026-02-18

Related Papers

Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study

Modern Rheumatology2024-11-074 citations